Table 1.
Characteristics of all patients meeting inclusion criteria, and patients with evaluable data.
| Patients with evaluable data (N=6394) |
||||||||
|---|---|---|---|---|---|---|---|---|
| All patientsa (N=10337) | All regimens (N=6394) | Efavirenz N=1140 (17.8%) | Nevirapine N=512 (8.0%) | Single PI N=3324 (52.0%) | Boosted PI N=401 (6.3%) | 3 NRTI N=517 (8.1%) | Other N=500 (7.8%) | |
| Mean age (years) | 42.8* | 45.7* | 47.1† | 45.5† | 45.1† | 45.8† | 46.7† | 45.4† |
| Male | 98.0% | 98.0% | 97.2% | 98.2% | 98.2% | 98.8% | 97.9% | 97.2% |
| Caucasian | 32.0%* | 31.1%* | 24.1%† | 30.9%† | 34.4%† | 27.3%† | 31.6%† | 39.0%† |
| African-American | 50.6%* | 51.3%* | 49.7%† | 52.3%† | 53.0%† | 52.5%† | 50.8%† | 41.6%† |
| Hispanic | 6.2%* | 6.0%* | 8.3%† | 5.3%† | 5.5%† | 5.0%† | 4.3%† | 7.4%† |
| Other race/ethnicity | 12.2%* | 10.8%* | 17.9%† | 11.5%† | 7.0%† | 15.3%† | 13.4%† | 12.1%† |
| Baseline CD4 cell count (mean) | 249 | 243 | 232† | 313† | 233† | 211† | 283† | 250† |
| Baseline log HIV-RNA (mean) | 4.5‡ | 4.6‡ | 4.8† | 4.5† | 4.6† | 4.7† | 4.5† | 4.5† |
a
Among all patients, 18.2% were on efavirenz, 8.2% on nevirapine, 51.2% on a single protease inhibitor (PI), 6.5% on boosted PI, 7.5% on three nucleoside reverse transcriptase inhibitors (NRTI), and 8.4% on other.
*
P<0.001 for evaluable versus non-evaluable data.
†
P<0.001 between regimen types.
‡
P=0.04 for evaluable versus non-evaluable data.